Journal article
Long-Term Follow-Up of Children in the HIVNET 012 Perinatal HIV Prevention Trial: Five-Year Growth and Survival
Journal of acquired immune deficiency syndromes (1999), Vol.64(5), pp.464-471
2013
DOI: 10.1097/QAI.0000000000000015
PMCID: PMC4172334
PMID: 24121753
Abstract
Objectives: To describe 5-year growth, survival, and long-term safety among children exposed to nevirapine or zidovudine in an African perinatal prevention trial, HIVNET 012.
Methods: All study children who were alive at the age 18 months were eligible for an extended follow-up study. Children whose families consented were enrolled and evaluated every 6 months from 24 to 60 months. At each visit, history, physical examination, and growth measures were taken. From these measurements, Z scores based on World Health Organization (WHO) standards were computed. Serious adverse event data were collected. Data from the initial and extended follow-up cohorts were included in the analysis.
Results: Five hundred twenty-eight study children were alive at the age 18 months, and 491 (426 HIV uninfected and 65 infected) were enrolled into the follow-up study. Both exposed but uninfected children and HIV-infected children were substantially below WHO growth standards for weight and height. Head circumference Z scores for uninfected children were comparable with WHO norms. Five-year survival rates were 93% for uninfected children versus 43% for infected children. Long-term safety and growth outcomes in the 2 study arms were similar.
Conclusions: Both infected and uninfected children in the 5-year HIVNET 012 follow-up showed poor height and weight growth outcomes, underscoring the need for early nutritional interventions to improve long-term growth of all infants born to HIV-infected women in resource-limited settings. Similarly, the low 5-year survival among HIV-infected children support the importance of early initiation of antiretroviral therapy. Both peripartum nevirapine and zidovudine were safe.
Details
- Title: Subtitle
- Long-Term Follow-Up of Children in the HIVNET 012 Perinatal HIV Prevention Trial: Five-Year Growth and Survival
- Creators
- Maxensia OWOR - Clinical Division, Makerere University—Johns Hopkins University Research Collaboration, Kampala, UgandaAnthony MWATHA - Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United StatesDeborah DONNELL - Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United StatesPhilippa MUSOKE - Clinical Division, Makerere University—Johns Hopkins University Research Collaboration, Kampala, UgandaFrancis MMIRO - Clinical Division, Makerere University—Johns Hopkins University Research Collaboration, Kampala, UgandaMelissa ALLEN - Science Facilitation Department, Family Health International, Durham, NC, United StatesJ. Brooks JACKSON - Department of Pathology, Johns Hopkins University, Baltimore, MD, United StatesMary Glenn FOWLER - Department of Pathology, Johns Hopkins University, Baltimore, MD, United StatesLaura A GUAY - Department of Epidemiology and Biostatistics, George Washington University School of Public Health and Health Services, Washington, DC, United States
- Resource Type
- Journal article
- Publication Details
- Journal of acquired immune deficiency syndromes (1999), Vol.64(5), pp.464-471
- DOI
- 10.1097/QAI.0000000000000015
- PMID
- 24121753
- PMCID
- PMC4172334
- NLM abbreviation
- J Acquir Immune Defic Syndr
- ISSN
- 1525-4135
- eISSN
- 1944-7884
- Publisher
- Lippincott Williams & Wilkins; Hagerstown, MD
- Language
- English
- Date published
- 2013
- Academic Unit
- Pathology; VPMA - Administration
- Record Identifier
- 9984046833602771
Metrics
15 Record Views